Drug Catalog - Product Detail
DILTIAZEM HCL ER (CD) - (CARTIA XT) CP 180MG 500
| NDC | Mfr | Size | Str | Form |
|---|---|---|---|---|
| 62037-0598-05 | ACTAVIS PHARMA | 500 | 180MG | CAPSULE |
PACKAGE FILES
Generic Name
DILTIAZEM HYDROCHLORIDE
Substance Name
DILTIAZEM HYDROCHLORIDE
Product Type
HUMAN PRESCRIPTION DRUG
Route
ORAL
Application Number
ANDA074752
Description
DESCRIPTION Diltiazem hydrochloride, USP is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1,5-Benzothiazepin-4(5 H )-one, 3-(acetyloxy)-5-[2-(dimethylamino) ethyl]-2, 3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+)- cis -. The chemical structure is: Diltiazem hydrochloride, USP is a white to off-white crystalline powder with a bitter taste. It is soluble in water, methanol, and chloroform. It has a molecular weight of 450.98. Diltiazem hydrochloride, USP is formulated as a once-a-day extended-release capsule containing 120 mg diltiazem hydrochloride (equivalent to 110.3 mg diltiazem), 180 mg diltiazem hydrochloride (equivalent to 165.45 mg diltiazem), 240 mg diltiazem hydrochloride (equivalent to 220.6 mg diltiazem), or 300 mg diltiazem hydrochloride (equivalent to 275.75 mg diltiazem). In addition, each capsule contains the following inactive ingredients: acetyltributyl citrate, ammonio methacrylate copolymer-NF, black iron oxide, cornstarch, D & C Red #28, D & C Yellow #10, D & C Yellow #10 Aluminum Lake, ethylcellulose, FD & C Blue #1 Aluminum Lake, FD & C Blue #2 Aluminum Lake, FD & C Red #40, FD & C Red #40 Aluminum Lake, gelatin-NF, magnesium stearate, methacrylic acid copolymer-NF, propylene glycol, polysorbate 80-NF, sucrose, talc USP, and titanium dioxide. The 180 mg and 240 mg capsules contain yellow iron oxide. In addition, the 240 mg capsule also contains red iron oxide. For oral administration. This drug meets USP Drug Release 9. Diltiazem hydrochloride chemical structure
How Supplied
HOW SUPPLIED Diltiazem Hydrochloride Extended-release Capsules, USP (Once-a-day dosage) Strength Quantity NDC Number Description 120 mg 90’s 500’s 62037-597-90 62037-597-05 White/orange opaque capsule imprinted with "Andrx 597" on one end and "120 mg" on the other. 180 mg 90’s 500’s 62037-598-90 62037-598-05 Yellow/orange opaque capsule imprinted with "Andrx 598" on one end and "180 mg" on the other. 240 mg 90’s 500’s 62037-599-90 62037-599-05 Light brown/orange opaque capsule imprinted with "Andrx 599" on one end and "240 mg" on the other. 300 mg 90’s 500’s 62037-600-90 62037-600-05 Orange/orange opaque capsule imprinted with "Andrx 600" on one end and "300 mg" on the other. NOTE: THE PRODUCT MAY HAVE AN ODOR. Storage Conditions: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive humidity. Dispense in tight, light resistant container as defined in USP. Manufactured By: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054 Rev. A 8/2020
Indications & Usage
INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules (once-a-day dosage) are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules (once-a-day dosage) are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
Dosage and Administration
DOSAGE AND ADMINISTRATION Patients controlled on diltiazem alone or in combination with other medications may be switched to diltiazem hydrochloride extended-release capsules (once-a-day dosage) at the nearest equivalent total daily dose. Higher doses of diltiazem hydrochloride extended-release capsules (once-a-day dosage) may be needed in some patients. Monitor patients closely. Subsequent titration to higher or lower doses may be necessary. There is limited general clinical experience with doses above 360 mg, but doses to 540 mg have been studied in clinical trials. The incidence of side effects increases as the dose increases with first-degree AV block, dizziness, and sinus bradycardia bearing the strongest relationship to dose. Hypertension: Adjust dosage to individual patient needs. When used as monotherapy, reasonable starting doses are 180 to 240 mg once daily, although some patients may respond to lower doses. Maximum antihypertensive effect is usually observed by 14 days of chronic therapy; therefore, schedule dosage adjustments accordingly. The usual dosage range studied in clinical trials was 240 to 360 mg once daily. Individual patients may respond to higher doses of up to 480 mg once daily. Angina : Dosages for the treatment of angina should be adjusted to each patient’s needs, starting with a dose of 120 or 180 mg once daily. Individual patients may respond to higher doses of up to 480 mg once daily. When necessary, titration may be carried out over a 7- to 14-day period. Concomitant Use with Other Cardiovascular Agents: Sublingual NTG: May be taken as required to abort acute anginal attacks during diltiazem hydrochloride therapy. Prophylactic Nitrate Therapy: Diltiazem hydrochloride may be safely coadministered with short- and long-acting nitrates. Beta-blockers: (see WARNINGS and PRECAUTIONS ) . Antihypertensives: Diltiazem hydrochloride has an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of diltiazem hydrochloride or the concomitant antihypertensives may need to be adjusted when adding one to the other.